<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691090</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-III-306</org_study_id>
    <nct_id>NCT03691090</nct_id>
  </id_info>
  <brief_title>Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer</brief_title>
  <official_title>PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial,
      comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel
      +cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a
      humanized anti-PD1 IgG4 monoclonal antibody.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, eligible subjects will be randomized into study arm or control arm. Treatment
      cycles of chemotherapy will be at most 6 cycles which would be decided by the investigators.
      Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) and
      overall survival (OS) will be the primary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS assessed by IRC</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by investigators</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 and 9 month OS rate</measure>
    <time_frame>approximately 6 and 9 months</time_frame>
    <description>OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antidrug Antibodies (ADAs)</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>To evaluate the incidence of ADAs against SHR-1210</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">548</enrollment>
  <condition>Advanced Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1210 + paclitaxel + cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+paclitaxel + cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 200mg</description>
    <arm_group_label>SHR-1210 + paclitaxel + cisplatin</arm_group_label>
    <other_name>camrelizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo+paclitaxel + cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel 175mg/m2</description>
    <arm_group_label>SHR-1210 + paclitaxel + cisplatin</arm_group_label>
    <arm_group_label>placebo+paclitaxel + cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin 75mg/m2</description>
    <arm_group_label>SHR-1210 + paclitaxel + cisplatin</arm_group_label>
    <arm_group_label>placebo+paclitaxel + cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed unresectable local advanced/recurrent or
             metastasis esophageal squamous cell carcinoma;

          2. No previous systemic anti-tumor treatment;

          3. Subjects must have at least one measurable tumor lesion per RECIST 1.1;

          4. Tissue samples should be provided for biomarkers (such as PD-L1) analysis;

          5. ECOG: 0-1;

          6. Adequate organ and bone marrow function;

        Exclusion Criteria:

          1. Allergic to monoclonal antibodies, any SHR-1210 components, paclitaxel, cisplatin and
             other platinum drugs;

          2. Prior therapy as follow:

               1. Anti-PD-1 or anti-PD-L1;

               2. Any experimental drugs within 4 weeks of the first dose of study medication;

               3. Received major operations or serious injuries within 4 weeks of the first dose of
                  study medication;

               4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy,
                  targeted therapy, etc.) within 4 weeks of the first dose of study medication;

          3. Not recovered to ≤CTCAE 1 from adverse events (except for hair loss) due to a
             previously anti-tumor treatment;

          4. Subjects with any active autoimmune disease or history of autoimmune disease;

          5. Pregnancy or breast feeding;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center of Sun-Yat Sen University (CCSYSU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qing Yang</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu HengRui Medicine Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Yang, MD</last_name>
    <phone>+86-21-68868570</phone>
    <phone_ext>836</phone_ext>
    <email>yangqing@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center of Sun-Yat Sen University (CCSYSU)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1Antibody</keyword>
  <keyword>advanced esophageal cancer</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

